HaemaLogiX Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $10M

  • Investors
  • 2

HaemaLogiX General Information

Description

Developer of a novel immuno-oncology and immune therapies designed for the treatment of hematologic malignancies and auto-immune diseases. The company is focused on the development and commercialization of monoclonal antibodies for the potential treatment of multiple myeloma with a key focus on treating multiple myeloma and early investigation of AL Amyloidosis and potentially other blood cancers, enabling clients to get targets that are highly specific to the cancer cells identified in blood cancers.

Contact Information

Website
www.haemalogix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 80 William Street
  • Suite 204
  • Woolloomooloo, New South Wales 2011
  • Australia
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 80 William Street
  • Suite 204
  • Woolloomooloo, New South Wales 2011
  • Australia

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HaemaLogiX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 08-Sep-2021 $10M 0000 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Startup
To view HaemaLogiX’s complete valuation and funding history, request access »

HaemaLogiX Patents

  • 52

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 18

    Granted

  • 12

    Pending

  • 000

    Expiring in next 12 mo

HaemaLogiX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020900948-A0 Composition and method Inactive 27-Mar-2020
AU-2018904581-A0 Method of treatment Inactive 03-Dec-2018
AU-2019392579-A1 Method of treatment Pending 03-Dec-2018 0000000000
EP-3890780-A1 Method of treatment Pending 03-Dec-2018 0000000000
US-20220031840-A1 Method of treatment Pending 03-Dec-2018 A61K39/395 0
To view HaemaLogiX’s complete patent history, request access »

HaemaLogiX Executive Team (7)

Name Title Board Seat
Damian Clarke-Bruce Co-Chief Executive Officer, Managing Director and Board Member
Bryce Carmine Co-Chief Executive Officer & Chairman
Dimitra Korkidas Chief Financial Officer and Company Secretary
Rosanne Dunn Ph.D Co-Founder, Chief Scientific Officer and Board Member
Hon Hunt Non-Executive Director
You’re viewing 5 of 7 executive team members. Get the full list »

HaemaLogiX Board Members (5)

Name Representing Role Since
Alan Liddle HaemaLogiX Co-Founder & Board Member 000 0000
Bryce Carmine HaemaLogiX Co-Chief Executive Officer & Chairman 000 0000
Geoff Nichol Self Board Member 000 0000
John Cullity Self Chairman 000 0000
Rosanne Dunn Ph.D HaemaLogiX Co-Founder, Chief Scientific Officer and Board Member 000 0000
To view HaemaLogiX’s complete board members history, request access »

HaemaLogiX Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HaemaLogiX Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Platinum Asset Management Asset Manager Minority 000 0000 000000 0
Cicada Innovations Accelerator/Incubator Minority 000 0000 000000 0
To view HaemaLogiX’s complete investors history, request access »

Ready to get started?

Request a free trial

HaemaLogiX FAQs

  • When was HaemaLogiX founded?

    HaemaLogiX was founded in 2014.

  • Who is the founder of HaemaLogiX?

    Rosanne Dunn Ph.D and Alan Liddle are the founders of HaemaLogiX.

  • Who is the CEO of HaemaLogiX?

    Damian Clarke-Bruce and Bryce Carmine are the CEOs of HaemaLogiX.

  • Where is HaemaLogiX headquartered?

    HaemaLogiX is headquartered in Woolloomooloo, Australia.

  • What is the size of HaemaLogiX?

    HaemaLogiX has 6 total employees.

  • What industry is HaemaLogiX in?

    HaemaLogiX’s primary industry is Biotechnology.

  • Is HaemaLogiX a private or public company?

    HaemaLogiX is a Private company.

  • What is HaemaLogiX’s current revenue?

    The current revenue for HaemaLogiX is 000000.

  • How much funding has HaemaLogiX raised over time?

    HaemaLogiX has raised $10M.

  • Who are HaemaLogiX’s investors?

    Platinum Asset Management and Cicada Innovations have invested in HaemaLogiX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »